Mouse Angiotensin I Converting Enzyme (ACE) CLIA Kit | ACE clia kit

Mouse Angiotensin I Converting Enzyme (ACE) CLIA Kit

Cat. Num. AAA2708439

• Gene Names: Ace; CD143; AW208573
• Reactivity: Mouse
• Applications: Chemiluminescence Immunoassay (CLIA)
• Synonyms: Angiotensin I Converting Enzyme (ACE); Mouse Angiotensin I Converting Enzyme (ACE) CLIA Kit; Angiotensin I Converting Enzyme; CD143; ACE1; DCP1; ACEI; ACE-I; Kininase II; Angiotensin-Converting Enzyme; Peptidyl-Dipeptidase A; Dipeptidyl Carboxypeptidase 1; Angiotensin-converting enzyme; soluble form; ACE clia kit

• Reactivity: Mouse
• Specificity: This assay has high sensitivity and excellent specificity for detection of Angiotensin I Converting Enzyme (ACE).; No significant cross-reactivity or interference between Angiotensin I Converting Enzyme (ACE) and analogues was observed.
• Sequence Length: 1312

• Applicable Applications for ACE clia kit: Chemiluminescence Immunoassay (CLIA)
• Assay Type: Double-antibody Sandwich
• Samples: Serum, plasma, tissue homogenates, cerebrospinal fluid, cell lysates, cell culture supernates and other biological fluids
• Detection Range: 54.9-40,000pg/mL
• Sensitivity: The minimum detectable dose of this kit is typically less than 21.5pg/mL
• Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiotensin I Converting Enzyme (ACE) were tested 20 times on one plate, respectively.; Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiotensin I Converting Enzyme (ACE) were tested on 3 different plates, 8 replicates in each plate.; CV(%) = SD/meanX100; Intra-Assay: CV<10%; Inter-Assay: CV<12%
• Test Principle: The microplate provided in this kit has been pre-coated with an antibody specific to Angiotensin I Converting Enzyme (ACE). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Angiotensin I Converting Enzyme (ACE). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Angiotensin I Converting Enzyme (ACE) level in the sample or standard.
• Preparation and Storage: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.; To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve (for reference only)

NCBI and Uniprot Product Information

• NCBI GI #: 73920183
• NCBI GeneID: 11421
• UniProt Accession #: P09470
• NCBI Official Full Name: Angiotensin-converting enzyme
• NCBI Official Synonym Full Names: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
• NCBI Official Symbol: Ace
• NCBI Official Synonym Symbols: CD143; AW208573
• NCBI Protein Information: angiotensin-converting enzyme
• UniProt Protein Name: Angiotensin-converting enzyme
• Protein Family: Acetylcholinesterase
• UniProt Gene Name: Ace
• UniProt Synonym Gene Names: Dcp1; ACE
• UniProt Entry Name: ACE_MOUSE

Uniprot Description

ACE: Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. Genetic variations in ACE may be a cause of susceptibility to ischemic stroke (ISCHSTR); also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors. Defects in ACE are a cause of renal tubular dysgenesis (RTD). RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). Genetic variations in ACE are associated with susceptibility to microvascular complications of diabetes type 3 (MVCD3). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new- onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Defects in ACE are a cause of susceptibility to intracerebral hemorrhage (ICH). A pathological condition characterized by bleeding into one or both cerebral hemispheres including the basal ganglia and the cerebral cortex. It is often associated with hypertension and craniocerebral trauma. Intracerebral bleeding is a common cause of stroke. Belongs to the peptidase M2 family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Protease; Membrane protein, integral; EC 3.4.15.1

Cellular Component: extracellular space; membrane; brush border membrane; lysosome; cytoplasm; plasma membrane; integral to membrane; basal plasma membrane; extracellular region; endosome; vesicle; external side of plasma membrane

Molecular Function: metallopeptidase activity; carboxypeptidase activity; zinc ion binding; mitogen-activated protein kinase kinase binding; mannosyl-oligosaccharide mannosidase activity; metal ion binding; drug binding; actin binding; glucosidase activity; endopeptidase activity; mitogen-activated protein kinase binding; amylase activity; chloride ion binding; peptidyl-dipeptidase activity; tripeptidyl-peptidase activity; hydrolase activity; trehalase activity; peptidase activity; protein binding; fucosidase activity; hexosaminidase activity; lytic transglycosylase activity; galactosidase activity; bradykinin receptor binding; exopeptidase activity; mannosidase activity

Biological Process: positive regulation of protein binding; positive regulation of apoptosis; neutrophil mediated immunity; response to lipopolysaccharide; positive regulation of systemic arterial blood pressure; regulation of angiotensin metabolic process; proteolysis; sensory perception of pain; peptide metabolic process; regulation of smooth muscle cell migration; peptide catabolic process; beta-amyloid metabolic process; regulation of blood pressure; kidney development; negative regulation of protein binding; vasoconstriction; positive regulation of neurogenesis; organ regeneration; eating behavior; arachidonic acid secretion; regulation of systemic arterial blood pressure by renin-angiotensin; heart contraction; spermatogenesis; hormone catabolic process; alveolus development; positive regulation of inflammatory response